Clinical plausibility: peer-reviewed evidence demonstrating preserved insulin stability and improved patient confidence in extreme conditions, and Health-economic validation: independent confirmation ...
FDA granted a narrow indication for CFD-FOLR1, targeting impaired folate transport into the CNS that drives developmental delay, seizures, movement disorders, and autistic features in some patients.